ABSTRACT

This report illustrates a case of a 60-year-old lady with type 2 diabetes mellitus who performs intermittent fasting (IF) diet, with the aim to lose her weight and indirectly reverse her diabetes mellitus, hypertension, and hyperlipidaemia. She managed to get the optimum blood pressure, lose 6 kg, and reduce her glycaemic control from 7.8% to 5.8% within 10 months period. However, she started to get episodes of symptomatic post prandial hypoglycaemia when she is about to achieve her target.

Keywords: Post Prandial Hypoglycaemia; Diabetes Mellitus; Intermittent Fasting

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is a chronic state of hyperglycaemia from insulin resistance and low pancreatic insulin secretion secondary to pancreatic β-cell dysfunction. According to recent national survey, there are almost 2 million adult Malaysians with established T2DM, and it is estimated to be another 5 million individuals with probable prediabetes (NHMS, 2019). This growing trend urges for sustainable approaches in battling this disease in the long run. Option of therapeutic lifestyle changes especially diet improvisation is getting more promising based on the ground-breaking molecular research worldwide (Wei et al., 2017). It is also reported by Lichtash et al. (2017) that there is therapeutic benefit of intermittent fasting in a 14-month case study as an alternative treatment for type 2 diabetes mellitus. More and more encouraging evidence of intermittent fasting (IF) diet as mentioned, has cultivated a growing interest over the recent years among doctors and patients. We report on a successful case of reversing T2DM to prediabetes state in a 60-year-old lady who started on IF with calorie restriction on top of standard pharmacological approach. We will also discuss about the subsequent episodic post prandial hypoglycaemia with symptoms that she had experienced.

CASE STUDY

This is a case of a 60-year-old lady with a 5-year-history of T2DM, hypertension and hyperlipidaemia under private general practice care. She is yet to achieve target glycaemic control with HbA1c of 7.8% and fasting blood glucose (FBS) range in between 5.1-11.3 mmol/L. Her previous medications were T. metformin 500mg twice daily and T. amlodipine 5mg daily. Upon beginning of care at our centre, we managed the suboptimal glycaemic control by adding sulphonylurea group and increasing dose of existing antihypertension. During subsequent follow up, we noticed her fasting blood glucose started to fall together with weight loss. It has come to our attention that she has been performing intermittent fasting (IF) upon being influenced heavily social media platform. Despite knowing this practice is not a recommended approach but she would still want to give a try and started to follow time and calorie restricted diet diligently. With time, she developed episodes of hunger pangs, tremor, sweating two to three hours after eating only during daytime. The range of her blood glucose level during events were between 2.4 to 3.7 mmol/L. These were reversible after taking sweets or sometimes sugar drink. She thought she would have her diabetes cured by doing IF, but at the same time, she is afraid that doctors would reject the idea of her unrecognised diet as it now has causing post prandial hypoglycaemia. On subsequent consultation, we assessed her level of understanding regarding hypoglycaemia and discussed about the crucial actions in response to it. We empowered self-monitoring blood glucose in this patient to act as quick check of the glucose status and self-motivation to allow flexibility of her chosen diet. We would expect low level of blood sugar during food restriction but surprisingly, she had post prandial hypoglycaemia instead. We advised to discontinue...
sulphonylurea agent and revised the meal selection and mealtime. As a result, we managed to prevent subsequent post prandial hypoglycaemia and overall, she had managed to lose 10% of bodyweight and achieved her target glycaemic index of HbA1c to 5.8% after 10 months of follow up.

Table 1: Timeline of patient treatment modality for type 2 diabetes and measured health parameters

| Month        | Treatment at time of visit | HbA1c (%) | Fasting Blood Glucose (mmol/L) | Weight (kg) | BMI (kg/m²) |
|--------------|---------------------------|-----------|-------------------------------|-------------|-------------|
| August 2020  | 1 Metformin 1500mg OD     | 8.4       |                               | 65.3        | 28.7        |
| September 2020| 2 Sulphonylurea 75mg OD  | 10.4      |                               | 62.0        | 24.9        |
| November 2020| 2 Sulphonylurea 75mg OD  | 7.6       | 5.6                           | 56.0        | 24.2        |
| March 2021   | 2 Sulphonylurea 75mg OD  | 5.9       | 6.6                           | 55.0        | 24.0        |
| June 2021    | 2 Sulphonylurea 75mg OD  | 5.8       | 5.9                           | 58.0        | 24.3        |

DISCUSSION

Lean et al., (2018) has proved that diet and lifestyle changes has now becoming the sustainable and potential modality for remission of type 2 diabetes mellitus. One of the growing interest in lifestyle changes is the practice of intermittent fasting (IF). It is a non-pharmacological approach which is evident to improve health outcome especially type 2 diabetes mellitus (Albosta & Bakke, 2021). With this promising benefit, our patient is one of the many individuals who are fascinated by the information on the media thence experimented intermittent fasting. Considering a patient-centred approach and not to further risk our patient to do intermittent fasting unsupervised, we discuss the available evidence and possible implications related to IF (Finnell et al., 2018).

Intermittent fasting describes the pattern of abstinence from eating limited calorie over a specified period from 12 hours to several days, on a rotational basis(Anton et al., 2018). There are three different regimens of IF such as alternate day fasting, periodic fasting and time-restricted fasting (Anton et al., 2018). Our patient is consistently doing the most popular regimen of restricted time to eat and fast. During 16 hours of food abstinence, metabolic switch at physiological level is entirely triggered as proposed by Anton et al., (2018), thus, we anticipated hypoglycaemia event to occur. Previous literature found dysglycaemia is seen in 11 out of 768 visits among medically supervised, water-only fasting patients (Finnell et al., 2018). This was seen when glycaemic control started to improve, our patient recorded symptoms of hypoglycaemia two to three hours after meal occasionally rather than before meal.

We postulate that this post prandial hypoglycaemia is due to the restoration of β- islet cell of pancreas from intermittent fasting, that is helping to enhance second phase insulin secretion (Wei et al., 2017). Moreover, having metformin on twice daily dosage has augmented the insulin sensitivity for optimum glucose utilisation. Other than that, glucose effectiveness is reported to be the greatest contributor in glucose disposal under fasting condition (equivalent to basal insulin concentration) that may explain the improvement of the glycaemic control towards diabetes remission (Lu et al., 2020).

Accompanying achieving glycaemic control, our patient managed to lose 5% of body weight from intermittent fasting.

CONCLUSION

Our case illustrates the sequalae of reversible episodic post prandial hypoglycaemia in intermittent fasting practice. This possible adverse event should be in consideration before prescribing patients to be on this therapeutic lifestyle change. Therefore, the future model of intermittent fasting needs to be supplemented with delicate multidisciplinary supervision in the setting of sufficient resource and expertise.

Conflict of Interest

We declare that there are no conflicts of interest relevant to this article.
ACKNOWLEDGEMENTS

We are grateful and acknowledges the valuable contributions of the involved patient in giving permission to share her information. We also would like to thank the Department of Family Medicine of International Islamic University of Malaysia for technical and material support. There is no source of funding for this article writing. The informed consent has been given by patient verbally prior to manuscript writing.

REFERENCES

Albosta, M., Bakke, J. (2021). Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians. Clinical diabetes and endocrinology, 7(1), 3.

Anton, S. D., Moehl, K., Donahoo, W. T., Marosi, K., Lee, S. A., Mainous, A. G., 3rd, Leeuwenburgh, C., & Mattson, M. P. (2018). Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring, Md.), 26(2), 254–268.

Fakhruddin, N. N. I., Shahar, S., Aziz, N. A., Yahya, H. M., & Rajikan, R. (2016). Which aging group prone to have inadequate nutrient intake?: TUA study (kumpulan penilaian yang mana lebicenderungterhadappengambilannutrien yang tidakmemenuhi?: Kajian TUA). Sains Malaysiana, 45(9), 1381–1391.

Finnell, J. S., Saul, B. C., Goldhamer, A. C., & Myers, T. R. (2018). Is fasting safe? A chart review of adverse events during medically supervised, water-only fasting. BMC complementary and alternative medicine, 18(1), 67.

Institute for Public Health (IPH), National Institute of Health, Ministry of Health Malaysia. (2020).NCDs – Non-Communicable Diseases: Risk Factors and other Health Problems: National Health Morbidity Survey (NHMS) 2019 Technical Report: Volume I, 26-28

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabe, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Stefanetti, R., Tre nell, M., Welsh, P., … Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet (London, England), 391(10120), 541–551.

Lichtash, C., Fung, J., & Ostoich, K. C., Ramos, M. (2017). Therapeutic use of intermittent fasting and ketogenic diet as an alternative treatment for type 2 diabetes in a normal weight woman: A 14-month case study. BMJ Case Reports. Published.

Lu, C. H., Teng, S. W., Wu, C. Z., Hsieh, C. H., Chang, J. B., Chen, Y. L., Liang, Y. J., Hsieh, P. S., Pei, D., & Lin, J. D. (2020). The roles of first phase, second phase insulin secretion, insulin resistance, and glucose effectiveness of having prediabetes in nonobese old Chinese women. Medicine, 99(12), e19562.

Wei, M., Brandhorst, S., Shelehchi, M., Mirzaei, H., Cheng, C. W., Budniak, J., Groshen, S., Mack, W. J., Guen, E., Di Biase, S., Cohen, P., Morgan, T. E., Dorff, T., Hong, K., Michalsen, A., Laviano, A., & Longo, V. D. (2017). Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science translational medicine, 9(377), eaat8700.